Updated just now · Live
Stock analysis, price data, and AI-powered insights for Cellectar Biosciences Inc (CLRB).
Cellectar Biosciences Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for CLRB.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). CLRB Stock Intelligence Report. [stoxpulse.com/stocks/clrb]
Disclaimer: The information on this page about Cellectar Biosciences Inc (CLRB) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Cellectar Biosciences Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Cellectar Biosciences Announces Subset of CLOVER W...
4h ago
Cellectar Biosciences Enrolls First Patient in Clr...
6d ago
StoxPulse AI results for CLRB: Pulse Score 50/100. Primary sentiment trends from 4 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$12.5M
P/E Ratio
—
EPS
$-1.41
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
Cellectar Biosciences Enrolls First Patient in Clr 125 Auger-Emitting Radioconjugate Phase 1B Clinical Trial Targeting Refractory Triple Negative Breast Cancer
Cellectar Biosciences Enrolls First Participant In Its Phase 1b Study Of CLR 121125 To Treat Triple Negative Breast Cancer
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)